Table 4.
Univariate and multivariate analysis of risk factors for time on treatment of hepatocellular carcinoma patients treated with sorafenib by the Cox proportional hazards model.
| Univariate |
Multivariatea |
|||
|---|---|---|---|---|
| Characteristics | HR (95% CI) | p-value | HR (95% CI) | p-value |
| Age (years) | 1.00 (0.98–1.02) | 0.68 | ||
| Albumin (mg/dL) | 1.62 (1.4–1.95) | 0.03 | ||
| Sex (male) | 1.06 (0.64–1.74) | 0.81 | ||
| MELD score | 1.13 (1.05–1.21) | 0.0009 | 1.08 (1.00–1.16) | 0.03 |
| Bilirubin | 1.66 (1.22–2.26) | 0.001 | ||
| AFP (ng/ml) | 1.09 (0.71–1.84) | 0.31 | ||
| INR | 1.44 (0.58–3.58) | 0.42 | ||
| ECOG PS | 1.06 (0.84–1.35) | 0.58 | ||
| Vascular invasion | 1.69 (1.01–2.85) | 0.04 | 1.73 (1.02–2.93) | 0.04 |
| Creatinine | 2.56 (1.04–6.2) | 0.04 | ||
| BMI (kg/m2) | 0.98 (0.93–1.04) | 0.71 | ||
| Child–Pugh score | 1.43 (1.10–1.87) | 0.007 | 1.34 (1.01–1.77) | 0.04 |
| Metastasis | 0.87 (0.53–1.41) | 0.57 | ||
| Sarcopenia | 1.82 (1.20–2.76) | 0.005 | 1.72 (1.12–2.64) | 0.001 |
| Ascites | 1.46 (0.88–2.44) | 0.14 | ||
HR: hazard ratio; CI: confidence interval; INR: international normalized ratio; AFP: alpha-fetoprotein; MELD: Model for End-stage Liver Disease; ECOG PS: Eastern Cooperative Oncology Group performance status; BMI: body mass index.
a
Bilirubin, creatinine and albumin were not included in the multivariate analysis to avoid colinearity, since they were included in either the Child–Pugh or MELD scores.